Clinical trials: Uncontrolled or Resistant Hypertension
Uncontrolled or Resistant Hypertension
A Trial of HRS-1780 in Participants With Uncontrolled Hypertension or Resistant Hypertension.
The study is being conducted to evaluate the efficacy and safety of HRS-1780 in participants with uncontrolled hypertension or resistant hypertension.
- Trial name
- NCT07708441
- Testing
- HRS-1780 tablet
- Where
- 2 sites in China
- Volunteers
- 914 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Hypertension, Resistant Hypertension
A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase II trial of VB19055 for 12 weeks in 240 adults with uncontrolled hypertension (including resistant hypertension).
- Conditions
- Hypertension, Resistant Hypertension, Uncontrolled Hypertension
- Trial name
- NCT07833098
- Testing
- VB19055 Dose A QD, VB19055 Dose B QD, VB19055 Dose C QD
- Where
- 24 sites in China
- Volunteers
- 240 people
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Uncontrolled Hypertension, Resistant Hypertension
A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
This is a Phase II, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, and effect of low, middle and high dose of SAL0120 versus placebo, administered once daily (QD) orally…
- Trial name
- NCT07790120
- Testing
- SAL0120
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Uncontrolled Hypertension, Resistant Hypertension
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally…
- Trial name
- BaxHTN (NCT06034743)
- Testing
- Baxdrostat
- Where
- 263 sites in United States, Argentina and 27 more
- Volunteers
- 796 people
- Sponsor
- AstraZeneca
Uncontrolled Hypertension, Resistant Hypertension
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
The purpose of this study is to measure the efficacy and safety of baxdrostat in participants with uHTN or rHTN. The main objective is to compare the difference in SBP change from baseline at Week 12 of treatment between…
- Trial name
- BaxAsia (NCT06344104)
- Testing
- Baxdrostat
- Where
- 93 sites in Argentina, Australia and 9 more
- Volunteers
- 326 people
- Sponsor
- AstraZeneca
Hypertension, Uncontrolled Hypertension
SMART Study in Real World
This study is a multicenter, single-arm, open-label and post-market study in a real world patient population with uncontrolled hypertension to document the long-term safety and efficacy of a renal mapping/selective renal…
- Conditions
- Hypertension, Uncontrolled Hypertension, Resistant Hypertension, Reduce Antihypertensive Drug Burden
- Trial name
- SMART-RW (NCT06780696)
- Testing
- SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- SyMap Medical (Suzhou), Ltd.
Hypertension, Blood Pressure, High
Registry to Evaluate the ROX COUPLER in Patients With Resistant or Uncontrolled Hypertension
The purpose of this registry is to evaluate the safety and performance of the ROX COUPLER in patients with treatment-resistant or uncontrolled hypertension.
- Conditions
- Hypertension, Blood Pressure, High, Blood Pressure, Resistant, Blood Pressure, Uncontrolled
- Trial name
- NCT01885390
- Testing
- ROX COUPLER
- Where
- 4 sites in Belgium, Netherlands and 1 more
- Volunteers
- 83 people
- Sponsor
- ROX Medical, Inc.
Resistant Hypertension, Uncontrolled Hypertension
Rapid Renal Sympathetic Denervation for Resistant Hypertension II
This is a global, multi-center, prospective, randomized, controlled study of the safety and effectiveness of renal denervation with the OneShot Renal Denervation System in patients with uncontrolled hypertension.
- Conditions
- Resistant Hypertension, Uncontrolled Hypertension, Renal Artery Ablation
- Trial name
- RAPID II (NCT01939392)
- Testing
- Renal Denervation (OneShot™ Renal Denervation System)
- Where
- Italy
- Sponsor
- Medtronic Endovascular